Sökning: WFRF:(Stroh C.) > Anticancer drugs of...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03505naa a2200493 4500 | |
001 | oai:DiVA.org:liu-87007 | |
003 | SwePub | |
008 | 130108s2003 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-870072 URI |
024 | 7 | a https://doi.org/10.1016/S1359-6446(02)02563-12 DOI |
040 | a (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Los, Marek Janu Institute of Experimental Dermatology, University of Muenster, Germany4 aut0 (Swepub:liu)marlo14 |
245 | 1 0 | a Anticancer drugs of tomorrow :b apoptotic pathways as targets for drug design |
264 | 1 | b Elsevier,c 2003 |
338 | a electronic2 rdacarrier | |
520 | a Apoptosis or programmed cell death is a set of ordered events that enables the selective removal of cells from tissue and is essential for homeostasis and proper function of multicellular organisms. Components of this signaling network, which include ligands, such as CD95, tumor necrosis factor (TNF) and TNF-related apoptosis-inducing ligand, as well as downstream molecules, such as caspases, Bcl-2 family members, and inhibitor-of-apoptosis proteins, which trigger and regulate apoptosis, are crucial targets for conventional drug development and gene therapy of cancer and other diseases. Here, we focus on apoptotic pathways and propose new potential molecular targets that could prove effective in controlling cell death in the clinical setting. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinsk bioteknologix Medicinsk bioteknologi0 (SwePub)304012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Medical Biotechnologyx Medical Biotechnology0 (SwePub)304012 hsv//eng |
653 | a bcl-2 protein family | |
653 | a caspase activation | |
653 | a cytochrome-c | |
653 | a interleukin-1-beta converting-enzyme | |
653 | a leukemia-cells | |
653 | a mice deficient | |
653 | a programmed cell-death | |
653 | a serine-protease | |
653 | a structural basis | |
653 | a trail-induced apoptosis | |
700 | 1 | a Burek, C. J.u Institute of Experimental Dermatology, University of Muenster, Germany4 aut |
700 | 1 | a Stroh, C.u Institute of Experimental Dermatology, University of Muenster, Germany4 aut |
700 | 1 | a Benedyk, K.u Dept of Tumor Biology Oncology Center, Maria Sklodowska-Curie Memorial Institute, Wybrzeze Armii Krajowej 15, PL-44100 Gliwice, Poland4 aut |
700 | 1 | a Hug, H.u TheraSTrat AGGewerbestrasse 25, CH-4123, Allschwil, Switzerland4 aut |
700 | 1 | a Mackiewicz, A.u Dept of Cancer Immunology, University of Medical Sciences, at Great-Poland Cancer Center, Poznan, Poland4 aut |
710 | 2 | a Institute of Experimental Dermatology, University of Muenster, Germanyb Dept of Tumor Biology Oncology Center, Maria Sklodowska-Curie Memorial Institute, Wybrzeze Armii Krajowej 15, PL-44100 Gliwice, Poland4 org |
773 | 0 | t Drug Discovery Todayd : Elsevierg 8:2, s. 67-77q 8:2<67-77x 1359-6446x 1878-5832 |
856 | 4 | u https://liu.diva-portal.org/smash/get/diva2:584216/FULLTEXT01.pdfx primaryx Raw objecty fulltext:preprint |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-87007 |
856 | 4 8 | u https://doi.org/10.1016/S1359-6446(02)02563-1 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.